ASH 2022 Conference Coverage

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology

Playback speed

December 21, 2022

Feat. H. Erba

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

U. Platzbecker

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

A. Vannucchi

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

G. Borthakur

ASH 2022 Conference Coverage

M. Della Porta

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

F. Passamonti

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

J. Mascarenhas

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

ASH 2022 Conference Coverage

J. Bewersdorf

ASH 2022 Conference Coverage

Login

Login

Join VuMedi

ASH 2022 Conference Coverage

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, & Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients With Polycythemia Vera

Importance of Early Management of Patients with Myelofibrosis (MF)

A proven CD123 targeted therapy for BPDCN

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With P…

MEDALIST Study: Multiple Episodes of Transfusion Independence With L…

Selected Updates in MDS

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

ASH 2022 Real-World Validation of Molecular International Prognostic…

ASH 2022: Management of Accelerated and Blast-Phase MPN

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF …

ASH 2022: What Is Complete HLA Match in 2022?

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in t…

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

Synergistic Activity of Luspatercept and Erythroid Stimulating Agent…

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MED…

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-…

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blin…

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safe…

Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on…

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib Ther…

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. D…